Infusion of analgesics using disposable infusion pumps is typically used to alleviate post-operative pain in procedures such as total knee replacement and total hip replacement. As a result, the growing number of orthopaedic operations and surgeries is likely to drive growth in the worldwide elastomeric infusion pumps market over the forecast period. The rising prevalence of chronic blood illnesses such as blood cancer is likely to fuel market expansion. The cost of elastomeric infusion pumps varies based on the kind of pump. Throughout the projected period, such a scenario is likely to stifle growth in the worldwide elastomeric infusion pumps market. Moreover, rigorous rules governing the use of plastics in elastomeric infusion pumps are projected to stymie market expansion.
According to Coherent Market Insights, Global Elastomeric Infusion Pumps Market is estimated to be valued at US$ 1,067.8 million in 2022 and is expected to exhibit a CAGR of 9.2% during the forecast period (2022-2030).
Key Companies in the Elastomeric Infusion Pumps Industry:
B. Braun Melsungen AG
The company was founded in 1838, headquartered in Germany. It is Manufacturer of healthcare supplies dedicated to protecting and improving people's health. The company offers products and product systems for anesthesia, intensive care, cardiology, extracorporeal blood treatment and surgeries, thereby enabling healthcare professionals and patients to make the right decisions in specific health-related conditions.
Fresenius Kabi
Fresenius Kabi AG, a health care company, specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition to help critically and chronically ill patients. In Jan. 26, 2023 kneat.com, inc., a leader in digitizing and automating validation and quality processes, announced it has signed a three-year SaaS Master Services Agreement ("the Agreement") with Fresenius Kabi Germany, a leading supplier of clinical nutrition, infusions, pharmaceuticals and medical technology. The agreement is effective immediately and allows the company to scale Kneat across all its business divisions and affiliates. In February 2, 2023 Formycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara®1
